Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System

<b>Background/Objectives</b>: Monoclonal antibodies (mAbs) have revolutionized multiple myeloma (MM) treatment. However, post-marketing data on their neuropsychiatric safety are limited. This study aimed to evaluate neuropsychiatric adverse events (AEs) related to mAbs used for MM throug...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Giuseppe Cicala (Autor), Giulia Russo (Autor), Vincenza Santoro (Autor), Tindara Franchina (Autor), Nicola Silvestris (Autor), Mariacarmela Santarpia (Autor), Edoardo Spina (Autor), Maria Antonietta Barbieri (Autor)
Formato: Libro
Publicado: MDPI AG, 2024-09-01T00:00:00Z.
Materias:
Acceso en línea:Connect to this object online.
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

Connect to this object online.

3rd Floor Main Library

Detalle de Existencias desde 3rd Floor Main Library
Número de Clasificación: A1234.567
Copia 1 Disponible